Pharmacological targeting of missense TP53 mutations has traditionally failed owing to the mutant heterogeneity, gain-of-function oncogenic properties and paradoxical stability of mutant p53 protein. A ‘p53-conditional’ proximity strategy promises to eradicate TP53 missense mutant-driven cancer by exploiting its abundance.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Farmer, G. et al. Nature 358, 83–86 (1992).
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L. & Vogelstein, B. Nature 358, 80–83 (1992).
Boeckler, F. M. et al. Proc. Natl Acad. Sci. USA 105, 10360–10365 (2008).
Puzio-Kuter, A. M. et al. Cancer Discov. 15, 1159–1179 (2025).
Vu, B. T. et al. ACS Med. Chem. Lett. 16, 34–39 (2025).
Sadagopan, A. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-025-02051-7 (2025).
Kong, L. et al. Clin. Transl. Med. 13, e1191 (2023).
Liu, J. et al. J. Am. Chem. Soc. 144, 12934–12941 (2022).
Kabir, M. et al. J. Am. Chem. Soc. 145, 14932–14944 (2023).
Raina, K. et al. Cell Chem. Biol. 31, 1490–1502.e1442 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Kabir, M. Hijacking mutant p53 abundance. Nat Chem Biol (2025). https://doi.org/10.1038/s41589-025-02054-4
Published:
Version of record:
DOI: https://doi.org/10.1038/s41589-025-02054-4
